News stories about Opko Health (NASDAQ:OPK) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Opko Health earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.310404274827 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Stock to Watch: Opko Health Inc (NASDAQ: OPK) – Alpha Beta Stock (alphabetastock.com)
- Opko Health, Inc. (OPK) registers a price change of 0.43% while Dynavax Technologies Corporation (DVAX) finishes … – Stocks Gallery (stocksgallery.com)
- Technical Facts tell us that more about the Opko Health, Inc. (OPK) – Wall Street Morning (wallstreetmorning.com)
- Opko Health, Inc. (OPK) noted a price change of -1.99% and Vermillion, Inc. (VRML) closes with a move of -5.29% – Stocks Gallery (stocksgallery.com)
- Analysts Alert: Opko Health Inc (OPK) – ExpertGazette (expertgazette.com)
Opko Health (NASDAQ OPK) opened at 6.83 on Tuesday. The stock has a 50 day moving average of $6.47 and a 200 day moving average of $6.73. The company’s market cap is $3.82 billion. Opko Health has a 52 week low of $5.85 and a 52 week high of $12.15.
Opko Health (NASDAQ:OPK) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The business had revenue of $314.20 million for the quarter, compared to the consensus estimate of $322.64 million. During the same quarter last year, the firm posted $0.02 EPS. The company’s revenue for the quarter was down 12.0% on a year-over-year basis. On average, analysts expect that Opko Health will post ($0.19) earnings per share for the current year.
Several equities research analysts recently commented on the stock. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $16.00 price objective on shares of Opko Health in a research note on Monday, September 25th. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Saturday, September 23rd. J P Morgan Chase & Co lowered shares of Opko Health from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $12.00 to $7.00 in a research note on Thursday, September 14th. Cantor Fitzgerald assumed coverage on shares of Opko Health in a research note on Thursday, August 17th. They set an “overweight” rating and a $20.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of Opko Health from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Opko Health presently has an average rating of “Buy” and a consensus target price of $13.97.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/10/10/opko-health-opk-earns-daily-news-sentiment-rating-of-0-09.html.
In other news, CEO Phillip Md Et Al Frost purchased 5,400 shares of the stock in a transaction dated Thursday, July 20th. The shares were acquired at an average cost of $6.46 per share, for a total transaction of $34,884.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $19,825,423.46. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders bought a total of 942,000 shares of company stock worth $5,767,553 over the last 90 days. Company insiders own 40.19% of the company’s stock.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.